Chiropractic Economics

AUGUST 4, 2024

The use of laser therapy in sports medicine is nothing new, although progressive applications for peak athletic performance are now going far beyond joint, muscle, tendon and ligament repair. We can’t wait to see what he does in 2026. low power and visible spectrum light ). as quickly as possible. as quickly as possible.

Ligaments 264

Ligaments Clinic Treatment Joints 264

OrthoSpineNews

APRIL 10, 2025

PsiFGuard is now part of Omnia Medicals comprehensive product offering for ambulatory sacro-iliac joint fusion procedures, a fast growing segment. This transaction is part of SpineGuard’s objective of reaching operational breakeven by the end of 2026. BOULDER, Co., The transfer operation of SpineGuard Inc. Ciaran Bolger, M.D.,

Scoliosis 52

Scoliosis Spine Joints Clients 52

Orthopedic Principles

MARCH 28, 2025

Courtesy: Prof Michael Hantes, ESSKA 1st Vice President Ivory Orange Modern Meet Our Team Instagram Post – 1 Lecture Topic: Osteochondritis Dissecans of the Knee Aim: Define the treatment algorithm for this disease. Physical Examination: Limp, alignment, joint palpation, range of motion, joint effusion.

X-ray 52

X-ray Diagnosis Knee Pain Joints 52

OrthoSpineNews

APRIL 16, 2025

PsiFGuard project co-developed with US company Omnia Medical During 2024, SpineGuard finalized the design and industrialization of its new “PsiFGuard” product intended for posterior sacroiliac joint fusion (“PSIF”). It could also be useful for prescribing bone-strengthening treatments post-operatively.

X-ray 52

X-ray Scoliosis Joints Prevention 52

OrthoSpineNews

JANUARY 29, 2025

OrthoPreserve’s implant addresses a significant treatment gap that exists due to the poor outcomes of the standard of care for meniscus tears, a partial meniscectomy, which removes the damaged tissue. OrthoPreserve’s proprietary technology has the potential to disrupt the standard of care and displace more invasive treatments.

Knee Pain 52

Knee Pain Treatment Joints Health 52

OrthoSpineNews

APRIL 4, 2025

The investments will fuel the companys continued growth and the launch of four groundbreaking 3D printed product lines in 2025 and 2026. This funding allows us to further scale our technology, expand access to truly personalized care, and continue setting new standards in orthopedic treatment. Pending FDA 510(k) approval.

Musculoskeletal 52

Musculoskeletal Joints Patients Treatment 52